市場調査レポート

商品コード

次世代シーケンシング：新たな臨床用途と世界市場

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

出版日: 2024年01月22日 | 発行: BCC Research

| ページ情報: 英文 492 Pages | 納期: 即納可能

価格

PDF & Excel (Single User License)

USD 5,500 862,180円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は、機能制限があるわけではありませんが、1回までとされます。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (2-5 Users)

USD 6,600 1,034,616円

レポートPDFおよびExcelを同一国内の5名迄にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は計5回までとされます。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 7,920 1,241,539円

レポートPDFおよびExcelを同一事業所に所属される方にて人数に制限なく共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。印刷機能に回数制限はありませんが、印刷したもののご利用はPDFのご利用者と同一範囲内です。

PDF & Excel (Enterprise License)

USD 9,504 1,489,847円

レポートPDFおよびExcelを同一企業の全ての事業所（資本100%子会社含む）にて人数に制限なく共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。印刷機能に回数制限はなく、同一企業内にて配布ご利用可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の臨床用途向け次世代シーケンシングの市場規模は、2023年の219億米ドルから、予測期間中は19.3%のCAGRで推移し、2028年には529億米ドルの規模に成長すると予測されています。

癌への臨床用途向け次世代シーケンシングの市場規模は、2023年の112億米ドルから、21.6%のCAGRで推移し、2028年には296億米ドルの規模に成長すると予測されています。また、癌以外への臨床用途向け次世代シーケンシングの市場規模は、2023年の107億米ドルから、16.8%のCAGRで推移し、2028年には233億米ドル近くに達すると予測されています。

当レポートでは、世界の臨床用途向け次世代シーケンシングの市場を調査し、市場概要、技術の背景、臨床NGSへの取り組みと新興技術、市場影響因子の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、技術・特許の動向、ESGの展望、競合情勢、主要企業のプロファイルなどをまとめています。

DNAの重要性
遺伝的変異と分析
遺伝子解析技術
臨床用途のシーケンシング
シーケンシング技術
DNA配列決定の歴史
サンガー配列決定技術
NGSプラットフォーム
ショートリードプラットフォーム
リングリードプラットフォーム
インフォマティクス技術
ベースコーリング
参照シーケンシングへのマッピング
バリアント分析
AI技術
臨床用シーケンシング技術の課題

第5章臨床NGSへの取り組みと新興技術

R&Dの取り組みとプログラム
1+ Million Genomes
ACTT (Access to Treatment and Testing)
ACGP (Access to Comprehensive Genomic Profiling Coalition)
Africa Pathogen Genomics Initiative
Blood Profiling Atlas
Cancer-ID
Cancer Moon Shots Program
China Precision Medicine Initiative
ClinGen
CTC Trap Consortium
diaRNAgnosis Project
Early Cancer Detection Consortium
EpiFemCare
France Genomic Medicine Plan
Friends of Cancer Research Project
Genomic Medicine Sweden
HCA-Organoid
Human Cell Atlas
Human Immunomics Initiative
Immunomonitor Consortium
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
Intervene
Liquid Biopsies and Imaging for Improved Cancer Care
Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
Liver Cancer Early Screening Comprehensive Prevention and Control Project
Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
Million Veteran Program
Medical Genome Initiative
MedSeq
Precision Medicine Initiative
Prompt
QuIP Project
SPHERES
Target ALS Diagnosis Initiative
TopMed
Treehouse Childhood Cancer Initiative
Very Rare Cancer Consortium
Worldwide Innovative Networking (WIN) Consortium
Single-Cell Research
Cambridge Single-Cell Analysis Core Facility
Harvard Medical School Single-Cell Core
Mayo Medical Genome Facility
National Center for Single-Cell Biology
Next-Generation Single-Cell Analysis Program
Single-Cell Analysis Core
UC San Francisco Single-Cell Analysis Center
The Wistar Institute of Anatomy and Biology
Population Sequencing Projects

第6章 NGSの臨床用途

癌への応用
精密医療
液体生検のバイオマーカー
メンデル性疾患へ応用
リプロダクティブヘルスへの応用
非侵襲的出生前検査
新生児スクリーニング
微生物学と感染症への応用
複雑な障害への応用

第7章臨床NGS産業

シーケンシング機器
企業
第三世代シーケンシング
シーケンシングインフォマティクス
ターゲット濃縮・増幅
CTCキャプチャ&検出
液体生検アッセイ
液体生検による癌スクリーニング/早期発見
健康を重視したDTC遺伝子検査：2つの市場モデル
DTC臨床健康遺伝子検査
非侵襲的出生前検査（NIPT）

第8章 ESGの展開

ESG：イントロダクション
NGSの持続可能性
ケーススタディ
BCCによる見解

第9章買収と戦略的提携

買収
戦略的提携
主要動向

第10章臨床NGS市場

市場力学
市場促進要因
COVID-19が臨床NGS市場に与える影響
臨床NGS市場：疾患カテゴリー別
臨床NGS市場：検査の複雑さ別
臨床NGS市場：検査目的別
腫瘍学における臨床NGS市場
市場：腫瘍の適応症別
腫瘍におけるNGS市場：検査目的別
腫瘍におけるNGS市場：検査の複雑さ別
心臓病における臨床NGS市場
心臓病におけるNGS市場：検査目的別
心臓病におけるNGS市場：検査の複雑さ別
メンデル性疾患における臨床NGS市場
メンデル性疾患における臨床NGS市場：検査の複雑さ別
代謝/免疫疾患における臨床NGS市場
代謝/免疫疾患におけるNGS市場：検査目的別
代謝/免疫疾患におけるNGS市場：検査の複雑さ別
神経内科の臨床NGS市場
神経内科のNGS市場：検査目的別
神経内科のNGS市場：検査の複雑さ別
リプロダクティブヘルスにおける臨床NGS市場
リプロダクティブヘルス市場：テスト用途別
リプロダクティブヘルスにおけるNGS市場：検査目的別
リプロダクティブヘルスにおけるNGS市場：検査の複雑さ別
微生物および感染症における臨床NGS市場
微生物および感染症におけるNGS市場：検査目的別
微生物および感染症におけるNGS市場：検査の複雑さ別
移植における臨床NGS市場
移植におけるNGS市場：臓器別
移植におけるNGS市場：検査目的別
移植におけるNGS市場：検査の複雑さ別
臨床NGS市場：地域別
腫瘍におけるNGSの世界市場：地域別
リプロダクティブヘルスにおけるNGSの世界市場：地域別
移植におけるNGSの世界市場：地域別

第11章特許レビュー

循環腫瘍細胞に関する特許
エクソソームに関する特許
無細胞DNAに関する特許
バイオマーカー関連の特許
癌診断におけるAIの使用に関する特許：考慮事項
液体生検の特許訴訟

第12章企業プロファイル

競合情勢
トップ5社
AGILENT TECHNOLOGIES INC.
BGI GENOMICS CO. LTD
ILLUMINA INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
その他の企業
ACCURAGEN HOLDINGS
ADAPTIVE BIOTECHNOLOGIES
ALCEN
AMBRY GENETICS
AMOY DIAGNOSTICS CO. LTD.
ANGLE PLC
APOSTLE SCIENCES
ARCEDI BIOTECH APS
ARMONICA TECHNOLOGIES INC.
ARUP LABORATORIES
ASURAGEN INC.
BAYLOR GENETICS
BECTON, DICKINSON AND CO.
BERRY GENOMICS BEIJING
BIOCAPTIVA LTD.
BIOCEPT INC.
BIODESIX
BIOFLUIDICA
BIOLIDICS LTD
BIOLOGICAL DYNAMICS
BIOMODAL
BIONANO GENOMICS
BIO-RAD LABORATORIES INC.
BIO-TECHNE
C2I GENOMICS
CAPIO BIOSCIENCES
CAREDX INC.
CARIS LIFE SCIENCE
CEGAT GMBH
CELL MICROSYSTEMS
CENTRILLION GENOMICS TECHNOLOGIES
CLARET BIOSCIENCE
CLEAR NOTE HEALTH
CLINICAL GENOMICS TECHNOLOGIES
CYCLOMICS
CYGNUS BIOSCIENCES CO. LTD.
DANAHER
DANTE LABS
DATAR CANCER GENETICS LTD.
DELFI DIAGNOSTICS
DIACARTA
DIAGNOLOGIX LLC
DIAGNOMICS INC.
DIAMIR BIO
DNALYTICS
DNANEXUS INC.
EARLYDIAGNOSTICS
EONE-DIAGNOMICS GENOME CENTER CO. LTD.
EPIC SCIENCES
EPIGENOMICS AG
EUROFINS GENOMICS
EVERLY HEALTH INC.
EXACT SCIENCES CORP.
EXOPERT
EXOSOMICS INC.
EZLIFE BIO
FABRIC GENOMICS INC.
F. HOFFMANN-LA ROCHE LTD
FLUXION BIOSCIENCES INC.
FREENOME HOLDINGS INC.
FULGENT GENETICS
FULL GENOMES CORP.
GENE BY GENE LTD.
GENEDX LLC
GENESEQ BIOSCIENCES
GENOMONCOLOGY LLC
GENOSABER
GRAIL INC.
GUARDANT HEALTH
HELIO GENOMICS
HELIX INC.
HTG MOLECULAR DIAGNOSTICS INC.
IMAGIA CANEXIA HEALTH
INCELLDX INC.
INEX INNOVATE PRIVATE LTD
INOVIQ
INTERPACE BIOSCIENCES INC.
INVITAE CORP.
INVIVOSCRIBE INC.
JABREHOO MED TECH CO. LTD.
JBS SCIENCE
JUMPCODE GENOMICS INC.
KONINKLIJKE PHILIPS N.V.
LABGENOMICS CO. LTD.
LABORATORY CORPORATION OF AMERICA HOLDINGS
LIQUID BIOPSY LABS
LUCENCE HEALTH INC.
LUNGLIFE AI INC.
MACROGEN INC.
MAPMYGENOME
MDXHEALTH INC.
MEDGENOME
MEDICOVER GENETICS
MENARINI SILICON BIOSYSTEMS SPA
MERCK KGAA
MICAREO RARE CELL DIAGNOSTICS
MICRONOMA INC.
MIR SCIENTIFIC
MUTANTDX
MYRIAD GENETICS INC.
NANOSTRING TECHNOLOGIES INC.
NATERA INC.
NEBULA GENOMICS
NEOGENOMICS LABORATORIES
NEW ENGLAND BIOLABS
NEW HORIZON HEALTH LTD.
NOVIGENIX SA
NOVOGENE CO. LTD.
NRICHDX INC.
NUPROBE INC.
NX PRENATAL INC.
ONCIMMUNE HOLDINGS PLC
ONCOCYTE CORP.
ONCODNA
OPKO HEALTH
ORCHID
OXFORD NANOPORE TECHNOLOGIES LTD.
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PANGAEA ONCOLOGY
PERSONAL GENOME DIAGNOSTICS INC.
PERSONALIS INC.
PHASE SCIENTIFIC
PIERIANDX
PREDICINE
PRENETICS GROUP
QCDX LLC
QUANTAPORE
QUANTGENE INC.
QUANTUMDX
QUEST DIAGNOSTICS
RARECELLS INC.
RAVGEN
REAL TIME GENOMICS
RESOLUTION BIOSCIENCE INC.
SAGA DIAGNOSTICS AB
SANO GENETICS
SCREENCELL
SEEKIN INC.
SEQUENCING.COM
SEVEN BRIDGES GENOMICS INC.
SINGLE TECHNOLOGIES
SMARTCATCH
STAGEZERO LIFE SCIENCES. LTD.
STRAND
STRATA ONCOLOGY
SYAPSE INC.
SYSMEX INOSTICS GMBH
TAKARA BIO INC.
TELEXOS GMBH
TWINSTRAND BIOSCIENCES INC.
TWIST BIOSCIENCE
UNCHAINED LABS
UNIVERSAL DX
VELA DIAGNOSTICS
VERACYTE
VOLITIONRX
VORTEX BIOSCIENCES
YOURGENE HEALTH
YIKON GENOMICS CO. LTD.

図表

List of Tables

Table A : Scope of the Report

Summary Table : Global Market for Clinical Applications of Next-Generation Sequencing, by Disease Class, Through 2028
Table 1 : Global Market for Clinical Next-Generation Sequencing, by Disease Type, Through 2028
Table 2 : Forces Influencing Growth in the Clinical NGS Market
Table 3 : Key Trends in the Clinical NGS Testing Market
Table 4 : Clinical NGS Industry Subsectors
Table 5 : DNA Chemical Building Blocks
Table 6 : DNA Translation and Transcription
Table 7 : Long-Range DNA Structure
Table 8 : Genetic Variant Types
Table 9 : Molecular Diagnostic Technology Platforms
Table 10 : Genome Coverage of PCR, Microarray and NGS Technology Platforms
Table 11 : Genetic Testing Coverage
Table 12 : Key Near- to Mid-term Segments of NGS Diagnostics
Table 13 : DNA Sequencing Historical Timeline, 1977-2023
Table 14 : Sequencing Technology Development, 1990-2020
Table 15 : Cost of Sequencing a Single Human Genome, 2001-2022
Table 16 : Summary of Sanger Sequencing
Table 17 : Improvements in Sanger Sequencing
Table 18 : NGS Technologies
Table 19 : Illumina NGS Workflow
Table 20 : Thermo Fisher Scientific NGS Workflow
Table 21 : NGS Bioinformatics Workflow
Table 22 : Sequence Annotation Steps
Table 23 : Types of AI in Healthcare
Table 24 : Future Challenges in Implementing Clinical NGS
Table 25 : Clinical NGS Research and Development Initiatives and Programs
Table 26 : Single-Cell Core Research Facilities
Table 27 : Population Sequencing Projects
Table 28 : Clinical NGS Near- to Mid-term Applications
Table 29 : Personalized Medicine Driven by Common Cancer Genetic Mutations
Table 30 : Liquid Biopsy Biomarkers
Table 31 : NGS-Based Cancer Diagnostics Market Segments
Table 32 : Mendelian Disorders Applications
Table 33 : Reproductive Health Screening Applications
Table 34 : Ethical Issues Associated with NIPT
Table 35 : Microbiology/Infectious Disease Applications
Table 36 : Complex Disorders Applications
Table 37 : Key Segments and Trends in the Clinical NGS Industry
Table 38 : NGS and 3GS Industry Company Positioning
Table 39 : Long-Read Sequencing Industry
Table 40 : Sequencing Informatics Industry
Table 41 : NGS Target Enrichment Industry
Table 42 : CTC Separations Industry
Table 43 : Liquid Biopsy Assay Industry: Company Focus
Table 44 : Examples of NGS-Based Liquid Biopsy Market Differentiation
Table 45 : Multi-Cancer Screening Test Desired Features
Table 46 : Shed Rates of Various Cancers
Table 47 : Cancer Screening Liquid Biopsy Industry
Table 48 : Thrive Earlier Detection (Exact Sciences) Cancer Targets
Table 49 : Colorectal Cancer Early Detection/Screening Liquid Biopsy Industry
Table 50 : Key Clinical Trials on Single- and Multi-Cancer Liquid Biopsy Assays
Table 51 : Clinical-Grade Health DTC Genetic Testing Companies
Table 52 : NIPT Industry
Table 53 : Key Focus Areas in ESG Metrics
Table 54 : ESG Rankings for Major Companies in the NGS Arena
Table 55 : Illumina 2030 ESG Targets
Table 56 : Clinical NGS Industry Acquisitions, January 2019-October 2023
Table 57 : Strategic Alliances in Clinical NGS, January 2019-April 2021
Table 58 : Key Forces Driving Growth in Clinical NGS and Their Implications
Table 59 : Global Market for Clinical NGS, by Disease Category, Through 2028
Table 60 : Global Market for Clinical NGS, by Test Complexity, Through 2028
Table 61 : Global Market for Clinical NGS, by Purpose of Test, Through 2028
Table 62 : Limitations of Tissue Biopsy in Cancer Applications
Table 63 : Low-Frequency Mutation Detection
Table 64 : Global Market for Clinical NGS in Oncology, by Indication, Through 2028
Table 65 : Five-Year Survival Rate for Ovarian Cancer
Table 66 : National Institutes of Health Liquid Biopsy Early Detection Initiative
Table 67 : Clinical Trials on Lung Cancer Liquid Biopsies
Table 68 : Global Market for Clinical NGS in Oncology, by Purpose of Test, Through 2028
Table 69 : MRI and Liquid Biopsy Methods
Table 70 : Early Detection Tissue of Origin Approaches
Table 71 : Global Market for Clinical NGS in Oncology, by Test Complexity, Through 2028
Table 72 : European Society of Medical Oncology NGS Recommendations for Metastatic Cancers, August 2020
Table 73 : Global Market for Clinical NGS in Cardiology Diagnostics, by Purpose of Test, Through 2028
Table 74 : NGS-Based Dilated Cardiomyopathy Test Providers
Table 75 : Global Market for Clinical NGS in Cardiology Diagnostics, by Test Complexity, Through 2028
Table 76 : Global Market for Clinical NGS in Mendelian Disorder Diagnostics, by Purpose of Test, Through 2028
Table 77 : Global Market for Clinical NGS in Mendelian Disorder Diagnostics, by Test Complexity, Through 2028
Table 78 : Global Market for Clinical NGS in Metabolic and Immune Disorder Diagnostics, by Purpose of Test, Through 2028
Table 79 : Multiple Sclerosis Diagnostic Technologies
Table 80 : Global Market for Clinical NGS in Metabolic and Immune Disorder Diagnostics, by Test Complexity, Through 2028
Table 81 : Global Market for Clinical NGS in Neurological Diagnostics, by Purpose of Test, Through 2028
Table 82 : Global Market for Clinical NGS in Neurological Diagnostics, by Test Complexity, Through 2028
Table 83 : Global Market for Clinical NGS in Reproductive Health, by Application, Through 2028
Table 84 : Global NGS-Based NIPT Market, by Risk Type, Through 2028
Table 85 : Global Market for Clinical NGS in Reproductive Health, by Purpose of Test, Through 2028
Table 86 : Global Market for Clinical NGS in Reproductive Health, by Test Complexity, Through 2028
Table 87 : NGS-Based Infectious Disease Landscape
Table 88 : Global Market for Clinical NGS-Based Microbiology and Infectious Disease Diagnostics, by Purpose of Test, Through 2028
Table 89 : Global Market for Clinical NGS-Based Microbiology and Infectious Disease Diagnostics, by Test Complexity, Through 2028
Table 90 : NGS in Infectious Disease Diagnostics
Table 91 : Global Market for Clinical NGS in Transplantations, by Organ, Through 2028
Table 92 : Transplant Procedures Performed in the U.S., by Organ, 2018-2020
Table 93 : Global Market for Clinical NGS in Transplantation, by Purpose of Test, Through 2028
Table 94 : Global Market for Clinical NGS in Transplantation, by Test Complexity, Through 2028
Table 95 : Global Market for Clinical NGS, by Region, Through 2028
Table 96 : Global Market for Clinical NGS in Oncology, by Region, Through 2028
Table 97 : Global Market for NGS in Reproductive Health, by Region, Through 2028
Table 98 : Global Market for Clinical NGS in Transplantation, by Region, Through 2028
Table 99 : Patent Activity on Circulating Tumor Cells (CTCs), by Country/Region, January 2010-June 2020
Table 100 : List of Select Patents Filed for Circulating Tumor Cells, 2020-2023
Table 101 : Patent Activity on Exosomes, by Country/Region, January 2010-December 2020
Table 102 : List of Select Patents Filed for Exosomes, 2020-2023
Table 103 : Patent Activity on Cell-Free DNA, by Country/Region, January 2010-December 2020
Table 104 : List of Select Patents Filed for Cell-Free DNA, 2020-2023
Table 105 : Patent Activity on Cancer Biomarkers, by Country/Region, January 2010-December 2020
Table 106 : List of Select Patents Filed for Cancer Biomarkers, 2020-2023
Table 107 : Status of NGS-Based Liquid Biopsy Patent Disputes, 2023
Table 108 : Global Market Ranking, 2022
Table 109 : Agilent Technologies Inc.: Company Snapshot
Table 110 : Agilent Technologies Inc.: Financial Performance, 2021 and 2022
Table 111 : BGI Genomics Co. Ltd: Company Snapshot
Table 112 : Illumina Inc.: Company Snapshot
Table 113 : Illumina Inc.: Financial Performance, 2021 and 2022
Table 114 : Qiagen: Company Snapshot
Table 115 : Qiagen NV: Financial Performance, 2021 and 2022
Table 116 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 117 : Thermo Fisher Scientific Inc.: Financial Performance, 2021 and 2022
Table 118 : AccuraGen Holdings: Company Snapshot
Table 119 : Adaptive Biotechnologies.: Company Snapshot
Table 120 : Alcen: Company Snapshot
Table 121 : Ambry Genetics: Company Snapshot
Table 122 : Amoy Diagnostics Co. Ltd.: Company Snapshot
Table 123 : Angle Plc: Company Snapshot
Table 124 : Apostle Sciences: Company Snapshot
Table 125 : Arcedi Biotech ApS: Company Snapshot
Table 126 : Armonica Technologies Inc.: Company Snapshot
Table 127 : Arup Laboratories: Company Snapshot
Table 128 : Asuragen Inc.: Company Snapshot
Table 129 : Baylor Genetics: Company Snapshot
Table 130 : BD: Company Snapshot
Table 131 : Berry Genomics Beijing: Company Snapshot
Table 132 : Biocaptiva Ltd.: Company Snapshot
Table 133 : Biocept Inc.: Company Snapshot
Table 134 : Biodesix: Company Snapshot
Table 135 : BioFluidica: Company Snapshot
Table 136 : Biolidics Ltd.: Company Snapshot
Table 137 : Biological Dynamics: Company Snapshot
Table 138 : biomodal: Company Snapshot
Table 139 : Bionano Genomics: Company Snapshot
Table 140 : Bio-Rad Laboratories Inc: Company Snapshot
Table 141 : Bio-Techne: Company Snapshot
Table 142 : C2i Genomics: Company Snapshot
Table 143 : Capio Biosciences: Company Snapshot
Table 144 : CareDx Inc.: Company Snapshot
Table 145 : Caris Life Sciences: Company Snapshot
Table 146 : CeGaT GmbH: Company Snapshot
Table 147 : Cell Microsystems: Company Snapshot
Table 148 : Centrillion Technologies: Company Snapshot
Table 149 : Claret Bioscience: Company Snapshot
Table 150 : ClearNote Health: Company Snapshot
Table 151 : ClearNote Health: Company Snapshot
Table 152 : Cyclomics: Company Snapshot
Table 153 : Cygnus Biosciences Co. Ltd: Company Snapshot
Table 154 : Danaher: Company Snapshot
Table 155 : Dante Labs: Company Snapshot
Table 156 : Datar Cancer Genetics: Company Snapshot
Table 157 : Delfi Diagnostics: Company Snapshot
Table 158 : DiaCarta: Company Snapshot
Table 159 : Diagnologix LLC: Company Snapshot
Table 160 : Diagnomics Inc.: Company Snapshot
Table 161 : Diamir Bio: Company Snapshot
Table 162 : DNAlytics: Company Snapshot
Table 163 : DNAnexus, Inc.: Company Snapshot
Table 164 : EarlyDiagnostics: Company Snapshot
Table 165 : Eone Diagnomics Genome Center Co. Ltd: Company Snapshot
Table 166 : Epic Sciences: Company Snapshot
Table 167 : Epigenomics AG: Company Snapshot
Table 168 : Eurofins Genomics: Company Snapshot
Table 169 : Everly Health Inc.: Company Snapshot
Table 170 : Exact Sciences Corp.: Company Snapshot
Table 171 : Exopert: Company Snapshot
Table 172 : Exosomics Inc.: Company Snapshot
Table 173 : EZlife Bio: Company Snapshot
Table 174 : Fabric Genomics Inc.: Company Snapshot
Table 175 : F. Hoffmann-La Roche Ltd: Company Snapshot
Table 176 : Fluxion Biosciences Inc.: Company Snapshot
Table 177 : Freenome Holdings Inc.: Company Snapshot
Table 178 : Fulgent Genetics: Company Snapshot
Table 179 : Full Genomes Corp.: Company Snapshot
Table 180 : Gene by Gene Inc.: Company Snapshot
Table 181 : GeneDx LLC: Company Snapshot
Table 182 : Geneseq Biosciences: Company Snapshot
Table 183 : GenomOncology LLC: Company Snapshot
Table 184 : GenoSaber: Company Snapshot
Table 185 : Grail Inc.: Company Snapshot
Table 186 : Guardant Health: Company Snapshot
Table 187 : Helio Genomics: Company Snapshot
Table 188 : Helix Inc.: Company Snapshot
Table 189 : HTG Molecular Diagnostics Inc.: Company Snapshot
Table 190 : Imagia Canexia Health: Company Snapshot
Table 191 : IncellDx: Company Snapshot
Table 192 : Inex Innovate Private Ltd.: Company Snapshot
Table 193 : INOVIQ: Company Snapshot
Table 194 : Interpace Biosciences Inc.: Company Snapshot
Table 195 : Invitae Corp.: Company Snapshot
Table 196 : Invivoscribe Inc.: Company Snapshot
Table 197 : Jabrehoo Med Tech Co. Ltd.: Company Snapshot
Table 198 : JBS Science: Company Snapshot
Table 199 : Jumpcode Genomics Inc.: Company Snapshot
Table 200 : Koninklijke Philips N.V.: Company Snapshot
Table 201 : Labgenomics: Company Snapshot
Table 202 : Laboratory Corporation of America Holdings: Company Snapshot
Table 203 : Liquid Biopsy Labs: Company Snapshot
Table 204 : Lucence Health Inc.: Company Snapshot
Table 205 : LungLife AI: Company Snapshot
Table 206 : Macrogen Inc.: Company Snapshot
Table 207 : MapmyGenome: Company Snapshot
Table 208 : mdxhealth: Company Snapshot
Table 209 : MedGenome: Company Snapshot
Table 210 : Medicover Genetics: Company Snapshot
Table 211 : Menarini Silicon Biosystems: Company Snapshot
Table 212 : Merck KGaA: Company Snapshot
Table 213 : MiCareo Inc.: Company Snapshot
Table 214 : Micronoma INC.: Company Snapshot
Table 215 : miR Scientific: Company Snapshot
Table 216 : MutantDx: Company Snapshot
Table 217 : Myriad Genetics, Inc.: Company Snapshot
Table 218 : NanoString Technologies Inc.: Company Snapshot
Table 219 : Natera Inc.: Company Snapshot
Table 220 : Nebula Genomics Inc.: Company Snapshot
Table 221 : NeoGenomics Laboratories: Company Snapshot
Table 222 : New England Biolabs: Company Snapshot
Table 223 : New Horizon Health: Company Snapshot
Table 224 : NOVIGENIX SA: Company Snapshot
Table 225 : Novogene Co Ltd: Company Snapshot
Table 226 : Nrichdx: Company Snapshot
Table 227 : NuProbe: Company Snapshot
Table 228 : NX Prenatal Inc.: Company Snapshot
Table 229 : Oncimmune Holdings PLC: Company Snapshot
Table 230 : OncoCyte Corp.: Company Snapshot
Table 231 : OncoDNA: Company Snapshot
Table 232 : OPKO Health Inc.: Company Snapshot
Table 233 : Orchid: Company Snapshot
Table 234 : Oxford Nanopore Technologies plc: Company Snapshot
Table 235 : PacBio: Company Snapshot
Table 236 : Pangaea Oncology: Company Snapshot
Table 237 : Personal Genome Diagnostics Inc: Company Snapshot
Table 238 : Personalis Inc.: Company Snapshot
Table 239 : Phase Scientific: Company Snapshot
Table 240 : PierianDx: Company Snapshot
Table 241 : Predicine: Company Snapshot
Table 242 : Prenetics Ltd.: Company Snapshot
Table 243 : QCDx: Company Snapshot
Table 244 : Quantapore: Company Snapshot
Table 245 : Quantgene Inc.: Company Snapshot
Table 246 : QuantuMDx Group Ltd.: Company Snapshot
Table 247 : Quest Diagnostics: Company Snapshot
Table 248 : Rarecells Inc.: Company Snapshot
Table 249 : Ravgen.: Company Snapshot
Table 250 : Real Time Genomics.: Company Snapshot
Table 251 : Resolution Bioscience Inc.: Company Snapshot
Table 252 : SAGA Diagnostics.: Company Snapshot
Table 253 : Sano Genetics: Company Snapshot
Table 254 : ScreenCell: Company Snapshot
Table 255 : SeekIn Inc.: Company Snapshot
Table 256 : Sequencing.Com: Company Snapshot
Table 257 : Seven Bridges Genomics: Company Snapshot
Table 258 : Single Technologies AB: Company Snapshot
Table 259 : SmartCatch: Company Snapshot
Table 260 : StageZero Life Sciences. Ltd.: Company Snapshot
Table 261 : Strand: Company Snapshot
Table 262 : Strata Oncology Inc.: Company Snapshot
Table 263 : Syapse Inc.: Company Snapshot
Table 264 : Sysmex Inostics Inc.: Company Snapshot
Table 265 : Takara Bio Inc: Company Snapshot
Table 266 : Telexos GmbH: Company Snapshot
Table 267 : TwinStrand Biosciences Inc.: Company Snapshot
Table 268 : Twist Bioscience: Company Snapshot
Table 269 : Unchained Labs: Company Snapshot
Table 270 : Universal DX: Company Snapshot
Table 271 : Vela Diagnostics: Company Snapshot
Table 272 : Veracyte Inc.: Company Snapshot
Table 273 : VolitionRx Ltd.: Company Snapshot
Table 274 : Vortex Biosciences: Company Snapshot
Table 275 : Yourgene Health: Company Snapshot
Table 276 : Yikon Genomics: Company Snapshot

List of Figures

Summary Figure : Global Market for Clinical Applications of Next-Generation Sequencing, by Disease Class, 2020-2028
Figure 1 : Timeline of the Advancement of Sequencing Technology
Figure 2 : How A Strong ESG Proposition Benefits Businesses
Figure 3 : The Ten Business Sustainability Trends Identified for 2022
Figure 4 : ESG-Adoption Level Across All the Industries, 2021 and 2022
Figure 5 : Key Sustainable Practices Being Implemented in Research Laboratories
Figure 6 : Agilent Technologies Inc.: Financial Performance, 2021 and 2022
Figure 7 : Agilent Technologies Inc.: Revenue Share, by Business Unit, 2022
Figure 8 : Agilent Technologies Inc.: Revenue Share, by Region, 2022
Figure 9 : Illumina Inc: Financial Performance, 2021 and 2022
Figure 10 : Illumina Inc.: Revenue Share, by Business Unit, 2022
Figure 11 : Illumina Inc.: Revenue Share, by Country/Region, 2022
Figure 12 : Qiagen NV: Financial Performance, 2021 and 2022
Figure 13 : Qiagen NV: Revenue Share, by Business Unit, 2022
Figure 14 : Qiagen NV: Revenue Share, by Region, 2022
Figure 15 : Thermo Fisher Scientific Inc.: Financial Performance, 2021 and 2022
Figure 16 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2022
Figure 17 : Thermo Fisher Scientific Inc.: Revenue Share, by Region, 2022

Product Code: BIO126E

Highlights:

The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a compound annual growth rate (CAGR) of 19.3% from 2023 through 2028.

The global market for clinical applications of next-generation sequencing for cancer is estimated to increase from $11.2 billion in 2023 to reach $29.6 billion by 2028, at a CAGR of 21.6% from 2023 through 2028.

The global market for clinical applications of next-generation sequencing for non-cancerous diseases is estimated to increase from $10.7 billion in 2023 to reach nearly $23.3 billion by 2028, at a CAGR of 16.8% from 2023 through 2028.

Report Scope:

The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies. The markets for NGS-based diagnostics are given for the years 2020, 2021, 2022, 2023 and 2028.

This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.

The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.

The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health, and transplant medicine.

Specific geographic markets are discussed, namely North America, Europe, Asia-Pacific, and the Rest of the World.

Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct-to-consumer testing; and noninvasive prenatal testing.

More than 100 companies in the clinical NGS industry are profiled in this report.

BCC Research also provides a summary of the recent, primary industry acquisitions and strategic alliances, including key alliance trends.

Report Includes:

41 data tables and 237 additional tables
An overview of the global market for emerging clinical applications of next-generation sequencing
Analysis of global market trends, featuring historical revenue data for 2020 to 2022, estimates for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by disease indication, test complexity, test purpose, application and geographic region
Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenarios and use of NGS-based diagnostics and technologies
Coverage of genome mapping programs, technological advances and innovations in NGS platforms, and the Ion Torrent Genexus System from Thermo Fisher Scientific and the Magnis NGS Prep System lfrom Agilent Technologies Inc
Description of NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT), and a discussion of their advantages
Market share analysis of the key companies and a look at their proprietary technologies, strategic alliances and other key market strategies, plus a patent analysis
Profiles of the leading players, including Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Agilent Technologies Inc., and BGI Genomics

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
What's New in This Report?
Geographic Breakdown
Segmentation Breakdown

Chapter 2 Summary and Highlights

Market Outlook
Market Summary

Chapter 3 Overview

Introduction
Liquid and Tissue Biopsy
Clinical NGS Market
Growth Drivers of Clinical NGS
Key Trends
Industry

Chapter 4 Technology Background

Importance of DNA
Genetic Variation and Analysis
Genetic Analysis Technologies
Sequencing in Clinical Applications
Sequencing Technologies
History of DNA Sequencing
Sanger Sequencing Technology
NGS Platforms
Short-Read Platforms
Long-Read Platforms
Informatics Technologies
Base Calling
Mapping to a Reference Sequence
Variant Analysis
Artificial Intelligence Technologies
Clinical Sequencing Technology Challenges

Chapter 5 Clinical NGS Initiatives and Emerging Technologies

R&D Initiatives and Programs
1+ Million Genomes
Access to Treatment and Testing (ACTT)
Access to Comprehensive Genomic Profiling Coalition (ACGP)
Africa Pathogen Genomics Initiative
Blood Profiling Atlas
Cancer-ID
Cancer Moon Shots Program
China Precision Medicine Initiative
ClinGen
CTC Trap Consortium
diaRNAgnosis Project
Early Cancer Detection Consortium
EpiFemCare
France Genomic Medicine Plan
Friends of Cancer Research Project
Genomic Medicine Sweden
HCA-Organoid
Human Cell Atlas
Human Immunomics Initiative
Immunomonitor Consortium
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
Intervene
Liquid Biopsies and Imaging for Improved Cancer Care
Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
Liver Cancer Early Screening Comprehensive Prevention and Control Project
Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
Million Veteran Program
Medical Genome Initiative
MedSeq
Precision Medicine Initiative
Prompt
QuIP Project
SPHERES
Target ALS Diagnosis Initiative
TopMed
Treehouse Childhood Cancer Initiative
Very Rare Cancer Consortium
Worldwide Innovative Networking (WIN) Consortium
Single-Cell Research
Cambridge Single-Cell Analysis Core Facility
Harvard Medical School Single-Cell Core
Mayo Medical Genome Facility
National Center for Single-Cell Biology
Next-Generation Single-Cell Analysis Program
Single-Cell Analysis Core
UC San Francisco Single-Cell Analysis Center
The Wistar Institute of Anatomy and Biology
Population Sequencing Projects

Chapter 6 Clinical NGS Applications

Introduction
Cancer Applications
Precision Medicine
Liquid Biopsy Biomarkers
Mendelian Disorders Applications
Reproductive Health Applications
Noninvasive Prenatal Testing
Newborn Screening
Microbiology and Infectious Disease Applications
Complex Disorders Applications

Chapter 7 Clinical NGS Industry

Sequencing Instrument Industry
Companies
Third-Generation Sequencing Industry
Sequencing Informatics Industry
Target Enrichment and Amplification Industry
CTC Capture and Detection Industry
Liquid Biopsy Assay Industry
Liquid Biopsy Cancer Screening/Early Detection Industry
Health-Focused DTC Genetic Testing Industry: Two Market Models
DTC Clinical Health Genetic Testing Industry
Noninvasive Prenatal Testing (NIPT) Industry

Chapter 8 ESG Development

Introduction to ESG
The Sustainability of NGS in Industry
Case Study
BCC Research Viewpoint

Chapter 9 Acquisitions and Strategic Alliances

Acquisitions
Strategic Alliances
Key Trends

Chapter 10 Clinical NGS Markets

Market Dynamics
Market Drivers
Impact of COVID-19 on the Clinical NGS Markets
Clinical NGS Market by Disease Category
Clinical NGS Market by Test Complexity
Clinical NGS Market by Purpose of Test
Clinical NGS Market in Oncology
Market by Indication in Oncology
NGS Market in Oncology by Purpose of Test
NGS Market in Oncology by Test Complexity
Clinical NGS Market in Cardiology
NGS Market in Cardiology by Purpose of Test
NGS Market in Cardiology by Test Complexity
Clinical NGS Market in Mendelian Disorders
NGS Market in Mendelian Disorders by Test Complexity
Clinical NGS Market in Metabolic/Immune Disorders
NGS Market in Metabolic/Immune Disorders by Purpose of Test
NGS Market in Metabolic/Immune Disorders by Test Complexity
Clinical NGS Market in Neurology
NGS Market in Neurology by Test Purpose
NGS Market in Neurology by Test Complexity
Clinical NGS Market in Reproductive Health
Reproductive Health Market by Test Application
NGS Market in Reproductive Health by Purpose of Test
NGS Market in Reproductive Health by Test Complexity
Clinical NGS Market in Microbiology and Infectious Diseases
NGS Market in Microbiology and Infectious Diseases by Purpose of Test
NGS Market in Microbiology and Infectious Diseases by Test Complexity
Clinical NGS Market in Transplantation
NGS Market in Transplantation by Organ Type
NGS Market in Transplantation by Purpose of Test
NGS Market in Transplantation by Test Complexity
Clinical NGS Market by Region
Global Market for NGS in Oncology by Region
Global Market for NGS in Reproductive Health by Region
Global Market for NGS in Transplantation by Region

Chapter 11 Patent Review

Patents on Circulating Tumor Cells
Patents on Exosomes
Patents on Cell-Free DNA
Patents Related to Biomarkers
Patent Considerations for the Use of Artificial Intelligence in Cancer Diagnostics
Liquid Biopsy Patent Litigation

Chapter 12 Company Profiles

Competitive Landscape
Top 5 Companies
AGILENT TECHNOLOGIES INC.
BGI GENOMICS CO. LTD
ILLUMINA INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
Other Companies
ACCURAGEN HOLDINGS
ADAPTIVE BIOTECHNOLOGIES
ALCEN
AMBRY GENETICS
AMOY DIAGNOSTICS CO. LTD.
ANGLE PLC
APOSTLE SCIENCES
ARCEDI BIOTECH APS
ARMONICA TECHNOLOGIES INC.
ARUP LABORATORIES
ASURAGEN INC.
BAYLOR GENETICS
BECTON, DICKINSON AND CO.
BERRY GENOMICS BEIJING
BIOCAPTIVA LTD.
BIOCEPT INC.
BIODESIX
BIOFLUIDICA
BIOLIDICS LTD
BIOLOGICAL DYNAMICS
BIOMODAL
BIONANO GENOMICS
BIO-RAD LABORATORIES INC.
BIO-TECHNE
C2I GENOMICS
CAPIO BIOSCIENCES
CAREDX INC.
CARIS LIFE SCIENCE
CEGAT GMBH
CELL MICROSYSTEMS
CENTRILLION GENOMICS TECHNOLOGIES
CLARET BIOSCIENCE
CLEAR NOTE HEALTH
CLINICAL GENOMICS TECHNOLOGIES
CYCLOMICS
CYGNUS BIOSCIENCES CO. LTD.
DANAHER
DANTE LABS
DATAR CANCER GENETICS LTD.
DELFI DIAGNOSTICS
DIACARTA
DIAGNOLOGIX LLC
DIAGNOMICS INC.
DIAMIR BIO
DNALYTICS
DNANEXUS INC.
EARLYDIAGNOSTICS
EONE-DIAGNOMICS GENOME CENTER CO. LTD.
EPIC SCIENCES
EPIGENOMICS AG
EUROFINS GENOMICS
EVERLY HEALTH INC.
EXACT SCIENCES CORP.
EXOPERT
EXOSOMICS INC.
EZLIFE BIO
FABRIC GENOMICS INC.
F. HOFFMANN-LA ROCHE LTD
FLUXION BIOSCIENCES INC.
FREENOME HOLDINGS INC.
FULGENT GENETICS
FULL GENOMES CORP.
GENE BY GENE LTD.
GENEDX LLC
GENESEQ BIOSCIENCES
GENOMONCOLOGY LLC
GENOSABER
GRAIL INC.
GUARDANT HEALTH
HELIO GENOMICS
HELIX INC.
HTG MOLECULAR DIAGNOSTICS INC.
IMAGIA CANEXIA HEALTH
INCELLDX INC.
INEX INNOVATE PRIVATE LTD
INOVIQ
INTERPACE BIOSCIENCES INC.
INVITAE CORP.
INVIVOSCRIBE INC.
JABREHOO MED TECH CO. LTD.
JBS SCIENCE
JUMPCODE GENOMICS INC.
KONINKLIJKE PHILIPS N.V.
LABGENOMICS CO. LTD.
LABORATORY CORPORATION OF AMERICA HOLDINGS
LIQUID BIOPSY LABS
LUCENCE HEALTH INC.
LUNGLIFE AI INC.
MACROGEN INC.
MAPMYGENOME
MDXHEALTH INC.
MEDGENOME
MEDICOVER GENETICS
MENARINI SILICON BIOSYSTEMS SPA
MERCK KGAA
MICAREO RARE CELL DIAGNOSTICS
MICRONOMA INC.
MIR SCIENTIFIC
MUTANTDX
MYRIAD GENETICS INC.
NANOSTRING TECHNOLOGIES INC.
NATERA INC.
NEBULA GENOMICS
NEOGENOMICS LABORATORIES
NEW ENGLAND BIOLABS
NEW HORIZON HEALTH LTD.
NOVIGENIX SA
NOVOGENE CO. LTD.
NRICHDX INC.
NUPROBE INC.
NX PRENATAL INC.
ONCIMMUNE HOLDINGS PLC
ONCOCYTE CORP.
ONCODNA
OPKO HEALTH
ORCHID
OXFORD NANOPORE TECHNOLOGIES LTD.
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PANGAEA ONCOLOGY
PERSONAL GENOME DIAGNOSTICS INC.
PERSONALIS INC.
PHASE SCIENTIFIC
PIERIANDX
PREDICINE
PRENETICS GROUP
QCDX LLC
QUANTAPORE
QUANTGENE INC.
QUANTUMDX
QUEST DIAGNOSTICS
RARECELLS INC.
RAVGEN
REAL TIME GENOMICS
RESOLUTION BIOSCIENCE INC.
SAGA DIAGNOSTICS AB
SANO GENETICS
SCREENCELL
SEEKIN INC.
SEQUENCING.COM
SEVEN BRIDGES GENOMICS INC.
SINGLE TECHNOLOGIES
SMARTCATCH
STAGEZERO LIFE SCIENCES. LTD.
STRAND
STRATA ONCOLOGY
SYAPSE INC.
SYSMEX INOSTICS GMBH
TAKARA BIO INC.
TELEXOS GMBH
TWINSTRAND BIOSCIENCES INC.
TWIST BIOSCIENCE
UNCHAINED LABS
UNIVERSAL DX
VELA DIAGNOSTICS
VERACYTE
VOLITIONRX
VORTEX BIOSCIENCES
YOURGENE HEALTH
YIKON GENOMICS CO. LTD.

次世代シーケンシング：新たな臨床用途と世界市場

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

目次

第1章イントロダクション

第2章サマリー・ハイライト

第3章概要

第4章技術の背景

第5章臨床NGSへの取り組みと新興技術

第6章 NGSの臨床用途

第7章臨床NGS産業

第8章 ESGの展開

第9章買収と戦略的提携

第10章臨床NGS市場

第11章特許レビュー

第12章企業プロファイル

List of Tables

List of Figures

Highlights:

Report Scope:

Report Includes:

Table of Contents

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Chapter 4 Technology Background

Chapter 5 Clinical NGS Initiatives and Emerging Technologies

Chapter 6 Clinical NGS Applications

Chapter 7 Clinical NGS Industry

Chapter 8 ESG Development

Chapter 9 Acquisitions and Strategic Alliances

Chapter 10 Clinical NGS Markets

Chapter 11 Patent Review

Chapter 12 Company Profiles

次世代シーケンシング：新たな臨床用途と世界市場

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 概要

第4章 技術の背景

第5章 臨床NGSへの取り組みと新興技術

第6章 NGSの臨床用途

第7章 臨床NGS産業

第8章 ESGの展開

第9章 買収と戦略的提携

第10章 臨床NGS市場

第11章 特許レビュー

第12章 企業プロファイル

List of Tables

List of Figures

Highlights:

Report Scope:

Report Includes:

Table of Contents

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Chapter 4 Technology Background

Chapter 5 Clinical NGS Initiatives and Emerging Technologies

Chapter 6 Clinical NGS Applications

Chapter 7 Clinical NGS Industry

Chapter 8 ESG Development

Chapter 9 Acquisitions and Strategic Alliances

Chapter 10 Clinical NGS Markets

Chapter 11 Patent Review

Chapter 12 Company Profiles

第1章イントロダクション

第2章サマリー・ハイライト

第3章概要

第4章技術の背景

第5章臨床NGSへの取り組みと新興技術

第7章臨床NGS産業

第9章買収と戦略的提携

第10章臨床NGS市場

第11章特許レビュー

第12章企業プロファイル